Louisiana State Employees Retirement System Makes New Investment in Medpace Holdings, Inc. (NASDAQ:MEDP)

Louisiana State Employees Retirement System purchased a new position in shares of Medpace Holdings, Inc. (NASDAQ:MEDP - Free Report) during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm purchased 6,500 shares of the company's stock, valued at approximately $1,992,000.

A number of other hedge funds also recently made changes to their positions in MEDP. Contravisory Investment Management Inc. purchased a new stake in shares of Medpace in the 4th quarter valued at about $26,000. RiverPark Advisors LLC bought a new stake in shares of Medpace in the 4th quarter valued at about $26,000. McGlone Suttner Wealth Management Inc. bought a new position in Medpace during the 4th quarter worth approximately $33,000. FinTrust Capital Advisors LLC bought a new stake in Medpace in the third quarter valued at approximately $30,000. Finally, Altshuler Shaham Ltd bought a new stake in Medpace during the 4th quarter valued at $27,000. 77.98% of the stock is currently owned by institutional investors.

Medpace Trading Down 2.1 %

NASDAQ:MEDP traded down $8.12 during trading hours on Thursday, reaching $374.32. 219,885 shares of the company were exchanged, compared to its average volume of 240,621. Medpace Holdings, Inc. has a twelve month low of $185.43 and a twelve month high of $419.42. The stock's 50-day moving average is $394.87 and its 200-day moving average is $319.06. The firm has a market cap of $11.60 billion, a PE ratio of 42.15, a price-to-earnings-growth ratio of 2.03 and a beta of 1.38.

Medpace (NASDAQ:MEDP - Get Free Report) last announced its earnings results on Monday, February 12th. The company reported $2.46 earnings per share for the quarter, topping the consensus estimate of $2.22 by $0.24. The company had revenue of $498.40 million during the quarter, compared to analyst estimates of $498.72 million. Medpace had a net margin of 15.00% and a return on equity of 63.98%. Medpace's revenue was up 26.5% compared to the same quarter last year. During the same quarter last year, the firm posted $2.12 earnings per share. As a group, research analysts anticipate that Medpace Holdings, Inc. will post 10.53 EPS for the current year.

Insider Activity

In other news, VP Susan E. Burwig sold 102 shares of the business's stock in a transaction dated Friday, March 15th. The stock was sold at an average price of $403.00, for a total transaction of $41,106.00. Following the completion of the transaction, the vice president now directly owns 15,181 shares of the company's stock, valued at $6,117,943. The sale was disclosed in a filing with the SEC, which is accessible through this link. In other news, VP Susan E. Burwig sold 102 shares of the stock in a transaction dated Friday, March 15th. The stock was sold at an average price of $403.00, for a total value of $41,106.00. Following the transaction, the vice president now owns 15,181 shares in the company, valued at approximately $6,117,943. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, major shareholder Medpace Investors, Llc sold 50,000 shares of the firm's stock in a transaction that occurred on Friday, February 16th. The stock was sold at an average price of $391.75, for a total transaction of $19,587,500.00. Following the sale, the insider now directly owns 5,539,947 shares in the company, valued at approximately $2,170,274,237.25. The disclosure for this sale can be found here. Over the last quarter, insiders sold 189,340 shares of company stock valued at $76,651,647. 20.30% of the stock is currently owned by company insiders.

Analyst Ratings Changes

A number of research firms have recently weighed in on MEDP. UBS Group raised shares of Medpace from a "neutral" rating to a "buy" rating and upped their target price for the stock from $282.00 to $452.00 in a research report on Thursday, February 15th. Robert W. Baird raised their target price on Medpace from $312.00 to $408.00 and gave the stock an "outperform" rating in a report on Wednesday, February 14th. StockNews.com lowered Medpace from a "buy" rating to a "hold" rating in a research note on Saturday, March 23rd. Finally, Deutsche Bank Aktiengesellschaft began coverage on shares of Medpace in a research report on Monday, March 18th. They issued a "hold" rating and a $395.00 price target on the stock. Two investment analysts have rated the stock with a hold rating and three have issued a buy rating to the company's stock. According to MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and a consensus target price of $382.00.

Medpace Company Profile

Medpace Holdings, Inc provides clinical research-based drug and medical device development services in North America, Europe, and Asia. The company offers a suite of services supporting the clinical development process from Phase I to Phase IV in various therapeutic areas. It provides clinical development services to the pharmaceutical, biotechnology, and medical device industries; and development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support services.